Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity
Here, we developed a novel oncolytic vaccinia virus (NOV) with the dual advantages of cancer selectivity and normal vessel reconstructive activity by replacing the viral thymidine kinase (vTk) and vaccinia growth factor (VGF) genes with genes encoding TNF-related apoptosis-inducing ligand (TRAIL) an...
Main Authors: | Su-Nam Jeong, So Young Yoo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1070 |
Similar Items
-
Oncolytic viro-chemotherapy exhibits antitumor effect in laryngeal squamous cell carcinoma cells and mouse xenografts
by: Wang Y, et al.
Published: (2019-04-01) -
Monitoring the Efficacy of Oncolytic Viruses via Gene Expression
by: Ashley Ansel, et al.
Published: (2017-11-01) -
Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules
by: Cole W. D. Peters, et al.
Published: (2021-08-01) -
Oncolytic Virotherapy in Glioma Tumors
by: Sergio Rius-Rocabert, et al.
Published: (2020-10-01) -
Oncolytic viruses as anticancer vaccines
by: Norman eWoller, et al.
Published: (2014-07-01)